ARCA biopharma, Inc. (ABIO): Price and Financial Metrics


ARCA biopharma, Inc. (ABIO): $2.22

-0.05 (-2.20%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ABIO to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

ABIO Stock Price Chart Interactive Chart >

Price chart for ABIO

ABIO Price/Volume Stats

Current price $2.22 52-week high $2.70
Prev. close $2.27 52-week low $1.74
Day low $2.18 Volume 40,078
Day high $2.31 Avg. volume 50,106
50-day MA $2.26 Dividend yield N/A
200-day MA $2.29 Market Cap 31.99M

ARCA biopharma, Inc. (ABIO) Company Bio


ARCA biopharma, Inc. operates as a biopharmaceutical company applying a precision medicine approach to developing and commercializing genetically targeted therapies for cardiovascular diseases. Its lead product candidate, Gencaro (bucindolol hydrochloride) is pharmacogenetically-targeted beta-adrenergic receptor antagonist, which is in the development for the treatment of atrial fibrillation in certain patients who also have heart failure (HF). The company also engages in the development of AB171, a thiol-substituted isosorbide mononitrate for the treatment of HF and peripheral arterial disease. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.


ABIO Latest News Stream


Event/Time News Detail
Loading, please wait...

ABIO Latest Social Stream


Loading social stream, please wait...

View Full ABIO Social Stream

Latest ABIO News From Around the Web

Below are the latest news stories about ARCA BIOPHARMA INC that investors may wish to consider to help them evaluate ABIO as an investment opportunity.

James Flynn Joins ARCA biopharma Board of Directors

WESTMINSTER, Colo., Dec. 19, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO) today announced that James Flynn has joined its Board of Directors. “We are pleased to welcome James Flynn to our Board,” said Robert E. Conway, Chairman of ARCA’s Board of Directors. “We appreciate his participation and input on the Company’s Board of Directors, including our process for evaluating strategic options for the Company.” Mr. Flynn is currently a Managing Member and Portfolio Manager of Nerium

Yahoo | December 19, 2022

One ARCA biopharma, Inc. (NASDAQ:ABIO) insider upped their stake by 5,155% in the previous year

Viewing insider transactions for ARCA biopharma, Inc.'s ( NASDAQ:ABIO ) over the last year, we see that insiders were...

Yahoo | November 14, 2022

ARCA biopharma Announces Third Quarter 2022 Financial Results

Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic optionsWESTMINSTER, Colo., Oct. 28, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported third quarter 2022 financial results and provided a corporate update. In May 2022, the Company retaine

Yahoo | October 28, 2022

ARCA biopharma Announces Second Quarter 2022 Financial Results

Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options WESTMINSTER, Colo., Aug. 02, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported second quarter 2022 financial results and provided a corporate update. Dr. Michael Bristow, ARCA’s Pr

Yahoo | August 2, 2022

Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Yahoo | July 18, 2022

Read More 'ABIO' Stories Here

ABIO Price Returns

1-mo -5.93%
3-mo 2.04%
6-mo -9.39%
1-year 23.33%
3-year -60.00%
5-year -93.42%
YTD -6.33%
2022 10.23%
2021 -46.38%
2020 -29.78%
2019 -3.86%
2018 -75.56%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.607 seconds.